Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Molecular Profile | ERBB3 positive |
Therapy | AMT-562 |
Indication/Tumor Type | esophagus adenocarcinoma |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
ERBB3 positive | esophagus adenocarcinoma | sensitive | AMT-562 | Preclinical - Pdx | Actionable | In a preclinical study, AMT-562 inhibited tumor growth in a patient-derived xenograft (PDX) model of ERBB3 (HER3)-positive esophageal adenocarcinoma (PMID: 37302522). | 37302522 |
PubMed Id | Reference Title | Details |
---|---|---|
(37302522) | AMT-562, a novel HER3-targeting antibody drug conjugate, demonstrates a potential to broaden therapeutic opportunities for HER3-expressing tumors. | Full reference... |